



ASX Announcement

8 April 2021

Chairman's Address to General Meeting

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure, today provides the Chairman's address to the General Meeting of Shareholders, to be held by way of a virtual webcast today at 4.00pm WST (Perth time).

Investors are reminded that pre-registration is a requirement of attendance at the virtual AGM, via the following link:

https://us02web.zoom.us/webinar/register/WN_LVXKIGUcSHebK2BoqIsBTw

This release dated 8 April 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Dr Thomas Duthy

Executive Director

tduthy@invextherapeutics.com

+61 402 493 727

Media

Margie Livingston

Ignite Communications

margie@ignitecommunications.com.au

+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter [@InvexThera_ASX](https://twitter.com/InvexThera_ASX)

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.



Chairman's Address
Invex Therapeutics Limited
General Meeting
8 April 2021

Good afternoon Ladies and Gentlemen, my name is Dr Jason Loveridge and I am a Founder and the Chairman of Invex Therapeutics Limited and will Chair today's meeting.

Online we have our directors:

- Professor Alexandra Sinclair, Executive Director, Chief Scientific Officer and co-Founder
- Dr Tom Duthy, Executive Director
- Mr David McAuliffe, Non-Executive Director
- Dr Megan Baldwin, Non-Executive Director and
- Ms Narelle Warren, Company Secretary

On behalf of the Board, we are pleased that you have taken the time to attend online and thank you for your support of the Company.

Given the significant health concerns attributed to the COVID-19 pandemic, in addition to guidelines and restrictions issued by the respective Australian state and federal governments, the Company considers that it is appropriate to hold this General Meeting as a virtual meeting, in a manner that is consistent with the No Action position from the Australian Securities and Investment Commission issued on Monday 29 March 2021 relating to the convening and holding of virtual shareholder meetings.

Before commencing with the formal part of today's meeting, being the approval of the options to Dr Megan Baldwin, I would now like to introduce Dr Baldwin to our investors.

Dr Baldwin is CEO and Managing Director of Opthea Limited a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications.



Under Dr Baldwin's leadership, Opthea has rapidly advanced its ophthalmology program through Phase I and Phase II clinical development, was added to the S&P/ASX 300 in June 2020 and in October 2020 completed a \$180 million initial public offering and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD.

We were naturally delighted that Megan decided to join the Board effective 16 February 2021 as a Non-Executive Director and at today's meeting we are seeking approval to issue Megan 400,000 incentive options in the Company to align her interests in Invex with that of our Shareholders. So welcome Megan to today's meeting and as a director of Invex.

Invex remains in a solid financial position with \$33.6 million in cash as at 31 December 2020, which is sufficient to fully fund a single Phase III clinical trial for Presendin for registration in Europe and potentially the US, pending the FDA feedback. We look forward to a productive year ahead at Invex.

Jason Loveridge, Ph.D
Chairman
Invex Therapeutics Limited
8 April 2021